Akile Karaaslan Eser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akile Karaaslan Eser has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Gülşen Kiliç
Department of Nursing, Faculty of Health Sciences, Başkent University. Ankara / Türkiye
1 shared publication Nur Izgu
1 shared publication- Semra Ercivan
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
1 shared publication - Sevcan Avcı Işık
Department of Nursing, Başkent University Faculty of Health Sciences, Ankara, Türkiye
1 shared publication - Sultan Ayaz-Alkaya
Gazi University Faculty of Nursing, Ankara, Turkiye
1 shared publication
Latest Publications
- 30 October 2026
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 42 (6)
Caregiver Self-Efficacy and Patient-Perceived Financial Toxicity in Advanced Cancer: The Mediating Role of Caregiver Burden
- 30 October 2026
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 42 (6)
Caregiver Self-Efficacy and Patient-Perceived Financial Toxicity in Advanced Cancer: The Mediating Role of Caregiver Burden
- Open Access
- 20 October 2026
- Published by Holistence Publications in Health Sciences Quarterly
- Vol. 6 (4) , 763-775
Polypharmacy and frailty in geriatric oncology patients with advanced cancer: A prospective observational study
Older adults with advanced cancer often have comorbidities, experience a symptom burden, take multiple medications, and are frail. To examine the relationship between polypharmacy and frailty, and to identify the factors that contribute to frailty in geriatric oncology patients aged 65 years and over with stage III-IV cancer. This prospective, observational, cross-sectional study was conducted between September 2025 and March 2026 at a university hospital in Türkiye. Data were collected from 200 inpatient and outpatient geriatric oncology patients via structured interviews and analysis of their medical records. The following scales were used to assess ECOG Performance Status and Edmonton Frailty Status: ECOG Performance Status Scale and Edmonton Frailty Scale (EFS). Polypharmacy was defined as the concurrent use of ≥5 medications. Polypharmacy was present in 83.5% of patients, with more than three-quarters exhibiting some degree of frailty. In the multivariable analysis, polypharmacy was strongly associated with frailty (OR: 8.22, 95% CI: 2.13–31.64, p=0.002). Older age (OR: 1.18, 95% CI: 1.06–1.32, p=0.003), stage IV cancer (OR: 2.79, 95% CI: 1.07–7.29, p=0.036), pain (OR: 4.45, 95% CI: 1.38–14.36, p=0.013), a history of falls (OR: 25.57, 95% CI: 1.96–334.10, p=0.013), and inpatient treatment setting (OR: 7.39, 95% CI: 1.99–27.50, p=0.003) were also independently associated with higher odds of frailty. The model demonstrated excellent discrimination (AUC = 0.934, 95% CI: 0.899–0.968). Polypharmacy is highly prevalent and strongly associated with frailty in geriatric oncology patients with stage III-IV cancer. Pain management, nutritional support and patient safety should also be considered for this group of patients. Further longitudinal studies are required to clarify the direction of this relationship and evaluate targeted interventions.
- 20 October 2026
- Published by Holistence Publications in Health Sciences Quarterly
- Vol. 6 (4) , 763-775
Open AccessPolypharmacy and frailty in geriatric oncology patients with advanced cancer: A prospective observational study
Older adults with advanced cancer often have comorbidities, experience a symptom burden, take multiple medications, and are frail. To examine the relationship between polypharmacy and frailty, and to identify the factors that contribute to frailty in geriatric oncology patients aged 65 years and over with stage III-IV cancer. This prospective, observational, cross-sectional study was conducted between September 2025 and March 2026 at a university hospital in Türkiye. Data were collected from 200 inpatient and outpatient geriatric oncology patients via structured interviews and analysis of their medical records. The following scales were used to assess ECOG Performance Status and Edmonton Frailty Status: ECOG Performance Status Scale and Edmonton Frailty Scale (EFS). Polypharmacy was defined as the concurrent use of ≥5 medications. Polypharmacy was present in 83.5% of patients, with more than three-quarters exhibiting some degree of frailty. In the multivariable analysis, polypharmacy was strongly associated with frailty (OR: 8.22, 95% CI: 2.13–31.64, p=0.002). Older age (OR: 1.18, 95% CI: 1.06–1.32, p=0.003), stage IV cancer (OR: 2.79, 95% CI: 1.07–7.29, p=0.036), pain (OR: 4.45, 95% CI: 1.38–14.36, p=0.013), a history of falls (OR: 25.57, 95% CI: 1.96–334.10, p=0.013), and inpatient treatment setting (OR: 7.39, 95% CI: 1.99–27.50, p=0.003) were also independently associated with higher odds of frailty. The model demonstrated excellent discrimination (AUC = 0.934, 95% CI: 0.899–0.968). Polypharmacy is highly prevalent and strongly associated with frailty in geriatric oncology patients with stage III-IV cancer. Pain management, nutritional support and patient safety should also be considered for this group of patients. Further longitudinal studies are required to clarify the direction of this relationship and evaluate targeted interventions.
- 25 October 2024
- Published by Türk Hemşireler Derneği in Türk Hemşireler Derneği Dergisi
- Vol. 5 (1) , 45-54
Kanser Tedavilerine Bağlı Onkolojik Aciller ve Hemşirelik Yönetimi
Kanser hastaları tedavi süreci boyunca pek çok kez acil servise başvurmak durumunda kalabilmektedir. Acil servise başvuru nedeni oluşturan ya da acil müdahale gerektiren durumlar onkolojik aciller olarak isimlendirilmektedir. Onkolojik aciller, kanser veya karmaşık tedaviler nedeniyle gelişen, kalıcı hasar ve ölüm riski dolayısıyla hızlı müdahale gerektiren akut durumlardır. Kanserin tanı anından hastalığın son aşamasına kadar herhangi bir dönemde görülebilmektedir. Onkolojik acil durumlar; tümör kaynaklı, metabolik kaynaklı, yapısal kaynaklı ve tedavi kaynaklı olmak üzere farklı şekillerde sınıflandırılabilmektedir. Bu makalede tedaviye bağlı onkolojik acillere yer verilmiştir. Tedaviye bağlı onkolojik aciller kapsamında; ekstravazasyon, sitokin salınım sendromu ve hemorajik sistit konularına ilişkin bilgiler derlenmiştir.
- 25 October 2024
- Published by Türk Hemşireler Derneği in Türk Hemşireler Derneği Dergisi
- Vol. 5 (1) , 45-54
Kanser Tedavilerine Bağlı Onkolojik Aciller ve Hemşirelik Yönetimi
Kanser hastaları tedavi süreci boyunca pek çok kez acil servise başvurmak durumunda kalabilmektedir. Acil servise başvuru nedeni oluşturan ya da acil müdahale gerektiren durumlar onkolojik aciller olarak isimlendirilmektedir. Onkolojik aciller, kanser veya karmaşık tedaviler nedeniyle gelişen, kalıcı hasar ve ölüm riski dolayısıyla hızlı müdahale gerektiren akut durumlardır. Kanserin tanı anından hastalığın son aşamasına kadar herhangi bir dönemde görülebilmektedir. Onkolojik acil durumlar; tümör kaynaklı, metabolik kaynaklı, yapısal kaynaklı ve tedavi kaynaklı olmak üzere farklı şekillerde sınıflandırılabilmektedir. Bu makalede tedaviye bağlı onkolojik acillere yer verilmiştir. Tedaviye bağlı onkolojik aciller kapsamında; ekstravazasyon, sitokin salınım sendromu ve hemorajik sistit konularına ilişkin bilgiler derlenmiştir.